In addition, the current results suggest that blocking ACVR2B signalling may be a promising strategy to counteract chemotherapy-induced muscle and bone loss without further damage to skeletal muscle oxidative capacity or mitochondria or the actual treatment of malignancies. Here, ACVR2B is linked to cancer.